You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

first line treatment for Non Small Cell Lung Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK Positive NSCLC Trial in Guangzhou (Loratinib)

Recruiting
  • ALK Positive Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial Perople's Hospital
Oct 19, 2023

NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Tislelizumab IV
  • +2 more
  • (no location specified)
Oct 25, 2023

Advanced NSCLC Trial in Jinan (almonertinib)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • Jinan, Shandong, China
    Degan Lu
Sep 12, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC Trial in Beijing (Pyrotinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Beijing, Beijing, China
    Peking Union Medical College
Feb 20, 2023

NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
  • Wuhan, Hubei, China
    Union hospital
Feb 20, 2023

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

NSCLC Trial (Tirelizumab;Chemotherapy monotherapy)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Tirelizumab；Chemotherapy monotherapy
  • (no location specified)
Jul 27, 2023

NSCLC Trial (Amivantamab, Lazertinib, Doxycycline)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Nov 7, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)

Recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • Combined therapy of anlotinib and aumolertinib
  • Kunming, Yunnan, China
    First Affiliated Hospital of Kunming University
Oct 22, 2023

Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

Recruiting
  • Nonsmall Cell Lung Cancer
  • HS-10365 capsules
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 22, 2023

Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)

Recruiting
  • Brain Metastases
  • Non-small Cell Lung Cancer
  • EGFR-TK Inhibitor
  • Stereotactic radiotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 27, 2023

NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 24, 2023

Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Recruiting
  • Lung Cancer Non-small Cell Stage IV
    • Athens, Greece
      Hellenic Cooperative Oncology Group
    Nov 14, 2022

    Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)

    Not yet recruiting
    • Advanced Squamous Non-Small-Cell Lung Cancer
    • (no location specified)
    Jun 11, 2023

    Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

    Not yet recruiting
    • Advanced Non-squamous Non-small-cell Lung Cancer
    • +2 more
    • Beijing, Beijing, China
      Peking University First Hospital Ethics Committee
    Sep 10, 2023

    Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)

    Recruiting
    • Advanced Non-squamous Non-Small-Cell Lung Cancer
    • Jinan, Shandong, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Dec 4, 2022

    NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Phase I - Mirdametinib - Level 1
    • +4 more
    • (no location specified)
    Jul 7, 2023

    NSCLC Trial in Ostrava (primary tumour radiotherapy, stereotactic body radiotherapy, maintenance radiotherapy)

    Recruiting
    • Non-small Cell Lung Cancer
    • primary tumour radiotherapy
    • +2 more
    • Ostrava, Moravian-Silesian Region, Czechia
      University Hospital Ostrava
    Dec 6, 2022

    Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)

    Not yet recruiting
    • Advanced Squamous Non Small Cell Lung Cancer
    • AK112, Carboplatin, Paxlitaxel
    • Tislelizumab, Carboplatin, Paxlitaxel
    • (no location specified)
    Apr 21, 2023

    Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)

    Not yet recruiting
    • Lung Cancer, Non-squamous, Non-small Cell
    • (no location specified)
    Nov 22, 2023

    Non Squamous Non Small Cell Lung Cancer Trial in Korea, Republic of (Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin)

    Not yet recruiting
    • Non Squamous Non Small Cell Lung Cancer
    • Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
    • Anam, Korea, Republic of
    • +7 more
    May 1, 2023

    Non-Small-Cell Lung Cancer Trial in Jinan (Recombinant human endostatin (Endostar))

    Recruiting
    • Non-Small-Cell Lung Cancer
    • Recombinant human endostatin (Endostar)
    • Jinan, Shandong, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Oct 8, 2022

    Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Peking, China
      Peking Union Medical College Hospital
    Nov 16, 2023